Arrowhead Corp (ARWR): Rasio rega marang prakiraan pendapatan

Arrowhead Pharmaceuticals (ARWR) relies on its unique TRiM platform for the precise suppression of pathogenic genes. The forward price-to-sales valuation reflects the dynamics of this advantage, with the latest value recorded as 15.00. Diversification of development in cardiology and pulmonology minimizes investment risks, while a neutral geopolitical status in the US ensures the stability of the company's research and development processes.

ARWR Arrowhead Pharmaceuticals, Inc.: Rega forward marang dodolan ing interval 04.07.2022 - 14.11.2026

Ringkesan rincian data analitis Arrowhead Corp (ARWR)

- rega saiki lan proyeksi nilai saham:

Rega saham Arrowhead Pharmaceuticals, Inc.|ARWR - Prakiraan konsensus analis

- data kapitalisasi bursa:

Nilai pasar Arrowhead Corp|ARWR - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Arrowhead Pharmaceuticals|ARWR - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku arrowheadpharma.com|ARWR - Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Rasio Total Utang marang Ekuitas Arrowhead Pharmaceuticals|ARWR - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Arrowhead Pharmaceuticals|ARWR - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Arrowhead Corp|ARWR - Utang jangka dawa|Utang jangka cendhak perusahaan Arrowhead Pharmaceuticals|Rasio cepet arrowheadpharma.com

- data bathi bisnis lan rasio investasi:

ARWR - Bathi perusahaan|Bathi mangsa ngarep Arrowhead Pharmaceuticals|ARWR - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Arrowhead Pharmaceuticals Inc|ARWR - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Arrowhead Corp|ARWR - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Arrowhead Pharmaceuticals|ARWR - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan arrowheadpharma.com|ARWR - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Arrowhead Pharmaceuticals

- statistik dodolan lan pendapatan perusahaan:

ARWR - Dodolan perusahaan|Prakiraan volume dodolan Arrowhead Pharmaceuticals, Inc.|ARWR - Multiplikator P/S|Multiplikator Forward P/S Arrowhead Corp

Ringkesan analisis perusahaan:Arrowhead Pharmaceuticals, Inc. ARWR

This indicator is calculated as the ratio of current market capitalization to projected revenue, allowing investors to assess the market discount or premium relative to future cash flows. By analyzing the forward P/S of the business, one can determine the valuation stability of Arrowhead Pharmaceuticals (ARWR), whose leadership in RNA interference and breakthrough liver disease treatments are driving elevated market expectations for future sales.

Analisis pesaing

Multiplikator Forward P/S MIRM (Mirum)|Multiplikator Forward P/S Dynavax Corp DVAX|ABUS - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IVA (Inventiva Corp)|Gyre Therapeutics, Inc. (GYRE) - Rasio rega marang prakiraan pendapatan|assemblybio.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Galectin Therapeutics, Inc.|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Genfit Corp GNFT|Multiplikator forward rega marang pendapatan DRRX (DURECT Corporation)|Multiplikator forward rega marang pendapatan aligos.com ALGS|Multiplikator Forward P/S BIVI (BioVie)|Rega forward marang dodolan GLMD|ENDRA Life Sciences Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Hepion Pharmaceuticals